C
Clinical Research IO
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VC✓Equity / VC | May 2024 | $0 | — | The Riverside Company | ↗ |
| LATE VC✓Equity / VC | Aug 2023 | $1.8M | $45M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Clinical Research IO is 87K monthly website visits, down 20.9% over the last three months. Clinical Research IO's team grew 31.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Clinical Research IO in the Boston ecosystem
The Clinical Research IO office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
NXT Ventures
Rally Ventures- BGBantam Group
Series A4 investors entered at this stage
- BPBoston Millennia Partners
Raymond Chang- MLMark Lacy
Abbhi Capital
Series B and later1 investor entered at this stage
The Riverside Company
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Clinical Research IO on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Clinical Research IO’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









